Boehringer says side effects of its obesity drug were consistent with rivals
FRANKFURT, May 10 (Reuters) - The side effects of an experimental obesity drug that was tested in Phase II by Zealand Pharma and partner Boehringer Ingelheim were consistent with those of similar GLP-1 based injectable drugs, a Boehringer executive told Reuters.
Paola Casarosa, head of therapeutic areas at Boehringer Ingelheim, also told Reuters that a larger follow-up trial in the third and last phase of drug testing was being prepared and that the two partners were discussing the trial design with key regulators across the world.
GLP-1 based injectable drugs include Novo Nordisk’s Wegovy and Ozempic as well as Eli Lilly's Mounjaro.
(Reporting by Ludwig Burger, Editing by Louise Heavens)
Terms and Privacy Policy